Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Tramadol vs FENTANYL-62
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
Moderate to moderately severe pain (FDA-approved),Chronic pain (off-label),Restless legs syndrome (off-label),Premature ejaculation (off-label),Osteoarthritis pain (off-label)
Anesthesia induction and maintenance,Management of acute pain,Treatment of breakthrough pain in opioid-tolerant patients,Off-label: epidural analgesia, procedural sedation
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
For analgesia: 50-100 mcg IV/IM every 1-2 hours as needed. For anesthesia: 2-50 mcg/kg IV. For PCA: 10-20 mcg IV with 5-10 min lockout. Transdermal: 12-100 mcg/h patch every 72 hours; start at 25 mcg/h in opioid-naive patients.
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
3–7 hours (terminal elimination half-life; prolonged in elderly, hepatic impairment, or with continuous infusion due to redistribution).
Hepatic via CYP2D6 and CYP3A4 to active metabolite O-desmethyltramadol (M1) and other inactive metabolites; undergoes conjugation.
Cr Cl 30-59 m L/min: extend dosing interval to every 12 hours. Cr Cl <30 m L/min: extend interval to every 12 hours and consider max dose 200 mg/day. Hemodialysis: administer dose after dialysis, with same interval adjustments.
GFR 30-60 m L/min: no adjustment for single doses; use with caution for chronic therapy. GFR 15-29 m L/min: consider dose reduction by 25-50% and monitor for CNS toxicity. GFR <15 m L/min: avoid transdermal formulations; reduce IV/oral doses by 50-75% and monitor closely.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interactions with drugs affecting CYP450 isoenzymes; risk of serotonin syndrome; risk of seizures; risk of suicide in patients with depression.
First trimester: Limited human data; animal studies show no clear teratogenicity at therapeutic doses but increased risk of neural tube defects at high doses. Second and third trimesters: Risk of neonatal respiratory depression, withdrawal syndrome, and reduced fetal growth with chronic use. Avoid or use lowest effective dose.
First trimester: Limited data; no clear evidence of major malformations in humans, but opioid exposure may be associated with neural tube defects in some studies. Second trimester: Risk of miscarriage or fetal growth restriction with prolonged use; no specific teratogenic effects identified. Third trimester: Risk of neonatal opioid withdrawal syndrome (NOWS) if used near term; respiratory depression at birth.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active metabolite M1 for analgesic effect. Poor metabolizers (7-10% of population) may experience reduced efficacy. Caution with serotonergic drugs due to risk of serotonin syndrome. Seizure risk increased in patients with epilepsy, history of seizures, or concomitant use of SSRIs, SNRIs, tricyclic antidepressants, or other drugs that lower seizure threshold. Dose adjustment needed in renal impairment (Cr Cl <30 m L/min: extended interval or avoid) and hepatic cirrhosis (reduce dose or extend interval). Avoid use in patients with severe hepatic impairment. Not recommended for children <12 years, or <18 years for tonsillectomy/adenoidectomy. Maximum single dose: 100 mg; maximum daily dose: 400 mg (300 mg in patients >75 years). Onset of action: 30-60 minutes; peak effect: 2-3 hours; duration: 4-6 hours.
Fentanyl-62 (bupivacaine and fentanyl) is used for epidural analgesia. Monitor for respiratory depression, especially in opioid-naive patients. Fentanyl is lipophilic, providing rapid onset but shorter duration than morphine. Co-administration with bupivacaine allows lower fentanyl doses. Avoid in patients with severe hypotension or hypersensitivity to amide anesthetics.
"The risk or severity of adverse effects can be increased when Tramadol is combined with Levorphanol."
"The risk or severity of adverse effects can be increased when Tramadol is combined with Diphenoxylate."
"The risk or severity of adverse effects can be increased when Tramadol is combined with Nalbuphine."
No interactions on record
Tramadol and FENTANYL-62 are distinct pharmacological agents. Tramadol belongs to the Opioid Agonist class and is primarily used for Moderate to moderately severe pain (FDA-approved)Chronic pain (off-label)Restless legs syndrome (off-label)Premature ejaculation (off-label)Osteoarthritis pain (off-label). FENTANYL-62 belongs to the Opioid Agonist class and is primarily used for Anesthesia induction and maintenanceManagement of acute painTreatment of breakthrough pain in opioid-tolerant patientsOff-label: epidural analgesia, procedural sedation. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. Tramadol carries a safety status of Category D/X, whereas FENTANYL-62 safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hepatic metabolism primarily via CYP3A4 to norfentanyl and other inactive metabolites; also undergoes N-dealkylation and hydroxylation.
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Renal (primarily as metabolites, <10% unchanged; ~75% total metabolites in urine), fecal (~9% total metabolites).
Approximately 20% bound to plasma proteins (primarily albumin).
~80–85% (primarily to alpha-1-acid glycoprotein, also albumin).
Approximately 2.6-3.0 L/kg (306-350 L for a 70 kg adult), indicating extensive tissue distribution.
3–6 L/kg (large Vd due to high lipophilicity; distributes extensively to tissues and fat).
Oral: approximately 70-75% (high first-pass metabolism). Rectal: similar to oral. Intramuscular: 100% (relative to IV).
Transdermal: ~92%; Buccal: ~50%; Intranasal: ~50–70%; Oral: <30% (extensive first-pass metabolism).
Child-Pugh Class A (mild): 50 mg every 12 hours. Child-Pugh Class B (moderate): 50 mg every 12 hours. Child-Pugh Class C (severe): not recommended.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50% and titrate slowly. Child-Pugh Class C: avoid use or reduce dose by 75% with extended dosing intervals; monitor for respiratory depression.
Age ≥16 years: same as adult dosing. Age 12-15 years: 50-100 mg orally every 4-6 hours; max 400 mg/day. For children <12 years: not recommended.
For procedural sedation: 0.5-2 mcg/kg IV/IM; for analgesia: 0.5-1 mcg/kg IV every 1-2 hours. For anesthesia: 2-5 mcg/kg IV for induction; maintenance 0.5-2 mcg/kg/h IV infusion. Transdermal not recommended for opioid-naive children.
Initiate at 25 mg orally every 6 hours as needed; titrate cautiously to 50 mg every 6 hours; max 300 mg/day. Consider creatinine clearance for dose adjustments.
Reduce initial dose by 50-75% due to increased sensitivity; titrate slowly. Avoid transdermal patches in frail elderly; use lowest effective dose. Monitor for respiratory depression and constipation. PCA may require lower bolus doses (5-10 mcg) and longer lockout intervals.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of abuse, addiction, and diversion; concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression; seizures; serotonin syndrome; suicide risk; adrenal insufficiency; severe hypotension; use in renal/hepatic impairment; anaphylaxis; use with MAOIs; use in pregnancy (neonatal withdrawal); use in breastfeeding.
Respiratory depression, risk of serotonin syndrome with serotonergic drugs, adrenal insufficiency, hypotension, bradycardia, seizures, serotonin syndrome, severe hypotension, and risk of misuse/abuse. Caution in patients with COPD, sleep apnea, head injury, increased intracranial pressure, biliary tract disease, and elderly/debilitated patients.
Hypersensitivity; concomitant use of MAOIs or within 14 days; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction; use in children <12 years for post-tonsillectomy/adenoidectomy pain.
Hypersensitivity to fentanyl or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; suspected or known GI obstruction; concurrent use with MAOIs or within 14 days of discontinuation; non-opioid-tolerant patients for transmucosal immediate-release formulations.
No significant food interactions. Grapefruit juice does not substantially affect tramadol metabolism. Avoid alcohol entirely due to additive CNS depression and increased risk of hepatotoxicity. St. John's Wort may reduce tramadol efficacy by inducing CYP3A4 and CYP2D6. High-fat meals may delay absorption but do not significantly affect overall exposure; take extended-release tablets consistently with or without food.
No food interactions are reported for epidural fentanyl. However, avoid grapefruit juice as it may affect fentanyl metabolism.
Tramadol is excreted into breast milk; relative infant dose estimated at 0.1-3.1% of maternal weight-adjusted dose. M/P ratio approximately 1.3. Monitor infant for drowsiness, feeding difficulties, and constipation. Avoid in mothers with CYP2D6 ultra-rapid metabolism due to increased opioid exposure.
Fentanyl is excreted into breast milk in low concentrations; the M/P ratio is approximately 0.4. Use with caution due to potential for infant sedation and respiratory depression; lowest effective dose for shortest duration. Risk of withdrawal in breastfed infants if maternal use is prolonged.
Increased clearance and volume of distribution in pregnancy may reduce serum levels; consider dose increase by 20-30% if inadequate analgesia. Avoid in third trimester near delivery due to risk of neonatal respiratory depression. Use lowest effective dose for shortest duration.
Increased clearance and volume of distribution in pregnancy may require higher doses or more frequent administration to achieve analgesic effect; titrate to effect, monitor for respiratory depression. No fixed dose adjustment; individualize based on pain severity and response.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush or chew extended-release tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness, respiratory depression, and overdose.,Tramadol may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not stop abruptly; withdrawal symptoms (anxiety, sweating, insomnia, pain) may occur. Taper under medical supervision.,Report symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness, twitching, nausea, diarrhea) immediately.,Seek emergency help if you experience slow/shallow breathing, severe drowsiness, or difficulty waking up.,Dispose of unused tramadol properly via drug take-back programs to prevent accidental ingestion or misuse.,Inform your doctor of all medications you take, especially antidepressants, antipsychotics, and pain relievers.,Pregnancy: avoid during labor; prolonged use may cause neonatal withdrawal syndrome. Breastfeeding: not recommended.,Grapefruit juice has not been shown to interact significantly, but avoid excessive intake.
Report any difficulty breathing or chest tightness immediately.,Do not drive or operate heavy machinery while receiving this medication.,Avoid alcohol and other CNS depressants.,Inform your doctor of all medications you are taking, especially other pain relievers or sleep aids.,This medication is for hospital use only; do not share with others.